Peptides

AOD 9604: The Complete Evidence-Based Guide to the Fat-Burning Peptide

Everything you need to know about AOD 9604 peptide—925 patients studied across 6 clinical trials. Learn the mechanism, dosing, safety profile, and realistic results.

15 min readMarch 6, 2026

NinjAthlete Team| Last reviewed: March 11, 2026

Medical Disclaimer: This article is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment.

Always consult a qualified healthcare professional before starting any peptide protocol, supplement regimen, or training program. Sources are cited with DOI/PubMed links where available. Read our editorial policy

Everything you need to know about AOD 9604—including clinical trial data from 925 patients, the science behind its fat-burning mechanism, proper dosing protocols, and what the research actually shows.

Key Takeaways

AOD 9604 is a 16-amino acid fragment of human growth hormone (HGH residues 176-191) that targets fat metabolism without affecting IGF-1 or insulin levels
In a 12-week clinical trial, participants lost an average of 2.6 kg vs. 0.8 kg in placebo (1.8 kg difference)
Six clinical trials involving 925 patients found AOD 9604 to be safe and well-tolerated with no serious adverse events
Development was terminated in 2007 after a 24-week trial of 536 subjects failed to show significant weight loss
AOD 9604 is banned by WADA for competitive athletes and remains in a regulatory gray area

What Is AOD 9604?

If you've been researching peptides for fat loss, you've likely encountered AOD 9604.

Originally developed by Metabolic Pharmaceuticals in Australia as an anti-obesity drug, this modified fragment of human growth hormone has gained significant traction in the biohacking and athletic performance communities.

But here's what most marketing-heavy articles won't tell you: AOD 9604's pharmaceutical development was actually terminated in 2007 after failing to demonstrate sufficient weight loss magnitude for regulatory approval in larger trials.

Does that mean it's useless? Not necessarily. The story is more nuanced than either the critics or the promoters would have you believe.

AOD 9604 (Advanced Obesity Drug 9604) is a synthetic peptide consisting of 16 amino acids.

It's derived from the C-terminal fragment of human growth hormone (HGH), specifically amino acids 176-191, with an additional tyrosine residue replacing the phenylalanine at the N-terminus.

This specific region of HGH is responsible for the hormone's fat-burning effects.

The key distinction between AOD 9604 and full HGH is selectivity.

While HGH affects multiple systems—including IGF-1 production, glucose metabolism, and tissue growth—AOD 9604 appears to retain only the lipolytic (fat-burning) properties.

This selectivity is what makes it interesting from both a research and practical standpoint.

If you're wondering how peptides differ from steroids and other performance compounds, that's an important distinction to understand before diving deeper.

What Does the Clinical Research Actually Show?

Unlike many peptides in the biohacking space, AOD 9604 has actually undergone substantial human clinical testing.

Over $50 million was invested in its development, and six randomized, double-blind, placebo-controlled trials were conducted between 2001 and 2007 in the UK and Australia. Here's what they found:

The 12-Week Trial: Promising Results

In one of the earlier randomized clinical trials, obese subjects receiving AOD 9604 at 1 mg/day lost an average of 2.6 kg over 12 weeks, compared to 0.8 kg in the placebo group.

That's a statistically significant difference of 1.8 kg (approximately 4 pounds) more fat loss than placebo.

Interestingly, higher doses didn't produce better results. A 10 mg/day dose actually led to smaller average weight reduction than the 1 mg dose, suggesting a ceiling effect or possibly even an inverse dose-response relationship.

AOD 9604 Clinical Trial Results - 2.6kg vs 0.8kg - 3.25x More Fat Loss Than Placebo

The 24-Week Trial: Where Things Got Complicated

The larger Phase IIb trial involved 536 obese subjects over 24 weeks and incorporated an intensive diet and exercise regimen for all participants.

The result?

AOD 9604 failed to produce statistically significant weight loss compared to placebo when lifestyle intervention was included.

This is the trial that ultimately led Metabolic Pharmaceuticals to terminate development in 2007.

However, it's worth noting that the intensive lifestyle intervention may have created a "floor effect", when the control group is already losing weight through diet and exercise, it becomes harder to demonstrate additional benefit from the drug.

Safety Data: 925 Patients, No Serious Adverse Events

Perhaps the most reassuring finding across all six trials was the safety profile.

Approximately 925 adult subjects participated in these clinical trials, and AOD 9604 was consistently found to be safe and well-tolerated.

Key safety findings include:

No effect on IGF-1 levels: Unlike full HGH, AOD 9604 did not increase insulin-like growth factor 1, confirming it doesn't stimulate tissue growth
No impact on glucose metabolism: Oral glucose tolerance tests showed AOD 9604 has no negative effect on carbohydrate metabolism—a significant advantage over HGH, which can cause insulin resistance
No immunogenicity: No anti-AOD 9604 antibodies were detected in any patients tested
No serious adverse events: No withdrawals or serious adverse events occurred related to AOD 9604 intake across all studies

Based on this safety data, AOD 9604 received Generally Recognized as Safe (GRAS) status for use in foods, drinks, and dietary supplements.

How Does AOD 9604 Work? The Science of Fat Burning

Understanding AOD 9604's mechanism helps explain both its potential benefits and its limitations.

The peptide works through several interconnected pathways:

Beta-3 Adrenergic Receptor Activation

The primary mechanism appears to involve upregulation of beta-3 adrenergic receptors (β3-AR) in adipose tissue.

A landmark study published in Endocrinology demonstrated that both HGH and AOD 9604 can restore the suppressed β3-AR levels found in obese mice to levels comparable with lean mice.

Here's the clincher: when researchers tested AOD 9604 in mice genetically engineered without β3-AR (knockout mice), the peptide failed to produce any fat loss.

This proves the effect is mediated specifically through this receptor pathway.

Beta-3 adrenergic receptors are found primarily on fat cells and, when activated, signal the cell to break down stored triglycerides into fatty acids for energy.

This is the same pathway activated during fasted cardio or high-intensity training.

How AOD 9604 Burns Fat - 3-Part Mechanism - Lipolysis, Lipogenesis Blocking, Beta-3 Activation

The Three-Part Fat Loss Mechanism

Stimulates lipolysis: AOD 9604 triggers the breakdown of stored fat (triglycerides) into free fatty acids and glycerol, making them available for energy
Inhibits lipogenesis: The peptide reduces activity of acetyl-CoA carboxylase, an enzyme crucial for creating new fat—essentially blocking new fat formation
Enhances fatty acid oxidation: Once fat is released, AOD 9604 may help increase the rate at which those fatty acids are burned for fuel

Importantly, AOD 9604 does NOT suppress appetite.

Unlike GLP-1 agonists (semaglutide, tirzepatide) that work centrally to reduce hunger, AOD 9604 works directly on fat tissue.

This means it won't help with cravings or overeating—it only affects how your body handles the fat you already have.

Understanding the difference between weight loss vs. fat loss is crucial here.

What AOD 9604 Doesn't Do

Unlike full HGH, AOD 9604 does NOT:

Increase IGF-1 levels (no anabolic/muscle-building effect)
Affect blood glucose or insulin sensitivity
Cause water retention or joint pain
Stimulate organ growth
Suppress appetite

AOD 9604 Dosage: What the Research Suggests

⚠️ Disclaimer: AOD 9604 is not FDA-approved for any medical use. The following information is based on clinical trial protocols and is provided for educational purposes only. Always consult a healthcare provider before using any peptide.

Clinical Trial Dosing

In human clinical trials, AOD 9604 was administered at doses ranging from 0.25 mg to 10 mg daily.

The most commonly cited effective dose from the positive 12-week trial was 1 mg/day orally.

Common Protocols in Practice

In the biohacking community, subcutaneous injection is the most common administration route, with typical protocols including:

AOD 9604 Dosage Protocol - 250-300mcg per day - Morning on Empty Stomach - 8-12 Week Cycle

Dosage: 250-300 mcg per day (some users split into two 150 mcg doses)
Timing: Morning on an empty stomach, at least 30-45 minutes before eating
Cycle length: 8-12 weeks
Administration: Subcutaneous injection into abdominal fat

Why Empty Stomach Matters

AOD 9604 works best when insulin levels are low. Eating raises insulin, which inhibits lipolysis.

Taking the peptide fasted—ideally first thing in the morning or before fasted cardio—maximizes its fat-burning potential.

If you're interested in fasting protocols, check out our guide on water fasting for complementary strategies.

AppPeptide Protocol Tracker

Track Your Protocol with PeptIQ

AI-powered dosing, smart reminders, and progress logging — all in one app. Never miss a dose.

Code NINJA — 20% off annual ($80/yr)

Download PeptIQ

Reconstitution and Storage

For injectable AOD 9604:

Add 2 mL bacteriostatic water to a 5 mg vial
Inject water slowly along the vial wall to avoid foaming
Gently swirl (don't shake) until dissolved
Store reconstituted peptide in refrigerator at 2-8°C (not freezer)

Reconstituted AOD 9604 typically remains stable for 4-6 weeks when properly refrigerated.

For more on peptide administration methods, see our article on oral peptides and bioavailability.

Potential Benefits of AOD 9604

Based on clinical research and mechanistic studies, AOD 9604 may offer several benefits:

1. Targeted Fat Loss

The primary researched benefit is enhanced lipolysis, particularly in stubborn fat deposits.

Animal studies showed effects particularly pronounced in abdominal fat, with obese Zucker rats demonstrating over 50% less body weight gain when treated with AOD 9604.

2. No Negative Metabolic Effects

Unlike many fat loss compounds, AOD 9604 doesn't negatively impact glucose metabolism, thyroid function, or create stimulant-like side effects.

This makes it potentially suitable for longer-term use and for individuals who can't tolerate stimulants.

If stress hormones are affecting your fat loss, read our guide on how cortisol sabotages fat loss.

3. Muscle Preservation

Because AOD 9604 doesn't affect protein metabolism or cause the catabolic effects seen with some fat loss drugs, it may help preserve lean muscle mass during a caloric deficit.

However, it won't actively build muscle like HGH.

4. Potential Joint and Cartilage Support

Emerging research suggests AOD 9604 may have applications beyond fat loss.

A 2015 study in rabbits found that AOD 9604 combined with hyaluronic acid showed the least cartilage degeneration compared to other treatment groups.

While preliminary, this aligns with anecdotal reports of improved joint comfort.

For dedicated recovery peptides, however, the Wolverine Complex (BPC-157 + TB-500) has more robust evidence.

Side Effects and Safety Considerations

AOD 9604 has one of the most favorable safety profiles among peptides, largely because of its extensive clinical testing.

Across 925 patients in six trials, the following was observed:

Reported Side Effects (Generally Mild)

Injection site reactions: Mild redness, swelling, or discomfort (most common)
Headache: Occasional, typically mild
Nausea: Rare, usually associated with first use
Flu-like symptoms: Reported occasionally in anecdotal accounts

What AOD 9604 Doesn't Cause

Importantly, AOD 9604 has NOT been linked to:

Water retention or edema
Carpal tunnel syndrome
Joint pain (actually may help joints)
Insulin resistance or glucose intolerance
Increased cancer risk (no IGF-1 elevation)
Hormonal shutdown or suppression

AOD 9604 vs. Other Fat Loss Compounds

How does AOD 9604 compare to other options for body recomposition?

AOD 9604 vs. Full HGH

HGH provides broader benefits including muscle growth, improved recovery, and anti-aging effects, but comes with significant side effects (insulin resistance, water retention, potential organ growth) and much higher cost. AOD 9604 offers targeted fat loss without these risks but won't build muscle or provide HGH's regenerative benefits.

AOD 9604 vs. Growth Hormone Secretagogues

Compounds like MK-677 (Ibutamoren) stimulate your body's natural HGH production, providing broader benefits but also elevating IGF-1.

MK-677 causes significant hunger increase, while AOD 9604 has no appetite effect.

For pure fat loss without other effects, AOD 9604 is more targeted.

AOD 9604 vs. Clenbuterol

Clenbuterol provides more rapid fat loss through beta-2 receptor stimulation but comes with stimulant side effects (tremors, increased heart rate, anxiety, insomnia).

AOD 9604 is slower-acting but much better tolerated, with no stimulant effects.

AOD 9604 vs. GLP-1 Agonists (Semaglutide/Tirzepatide)

GLP-1 agonists produce dramatically more weight loss (15-20%+ of body weight) primarily through appetite suppression.

They're FDA-approved but come with GI side effects and require ongoing use. AOD 9604 works differently (direct fat metabolism) and produces more modest results, but doesn't suppress appetite or cause nausea.

For more on prescription options, see our article on semaglutide for weight loss.

Stacking AOD 9604 with Other Peptides

Many users combine AOD 9604 with other peptides for enhanced results. Common stacking approaches include:

For Enhanced Fat Loss

AOD 9604 + CJC-1295/Ipamorelin: Adding a growth hormone releasing peptide (GHRP) can enhance overall fat oxidation and provide additional recovery benefits.

The CJC-1295/Ipamorelin combination increases natural GH pulses, potentially synergizing with AOD 9604's direct lipolytic action.

For Body Recomposition with Recovery

AOD 9604 + BPC-157: For athletes dealing with nagging injuries while trying to lean out, combining AOD 9604 with BPC-157 addresses both goals.

BPC-157's tissue-healing properties complement AOD 9604's fat metabolism effects without interference.

For a comprehensive overview of peptide options, check out our complete guide to peptide therapy for athletes.

What Results Can You Realistically Expect?

Setting realistic expectations is crucial. Based on clinical data and user reports:

AOD 9604 Expected Results Timeline - Week 1-12 - When to Expect Fat Loss Results

Timeline of Effects

Weeks 1-2: Minimal visible changes; peptide is building in your system
Weeks 3-4: Some users report subtle improvements in body composition
Weeks 6-8: More noticeable fat reduction, particularly in stubborn areas
Weeks 8-12: Peak effects; clinical trials showed significant results at 12 weeks

Realistic Fat Loss Expectations

Based on the clinical trial data showing 1.8 kg additional fat loss over 12 weeks compared to placebo, expect modest rather than dramatic results.

AOD 9604 appears to enhance fat loss by roughly 0.3-0.5 lbs per week beyond what you'd achieve with diet and exercise alone.

This isn't a magic bullet. You still need a caloric deficit for fat loss to occur.

Think of AOD 9604 as an accelerator, not a replacement for proper nutrition and training.

For nutrition guidance, check out our ultimate guide to high protein meal prep.

Legal Status and Athletic Testing

WADA Status: Banned for Athletes

Critical for competitive athletes: AOD 9604 is on WADA's prohibited list. If you're subject to drug testing in any sport, AOD 9604 will cause you to fail a test and face disqualification. This applies even to "natural" bodybuilding federations and most amateur sports.

FDA Status: Not Approved

The FDA has not evaluated AOD 9604 for safety, effectiveness, or manufacturing standards for therapeutic use.

While it has GRAS status for food/supplement use, injectable forms exist in a regulatory gray area.

The FDA has taken action against compounding pharmacies producing AOD 9604 for injection.

Frequently Asked Questions

How long does AOD 9604 stay in your system?

AOD 9604 has a relatively short plasma half-life of 2-3 hours. However, its metabolic signaling effects can persist for up to 24 hours, which is why once-daily dosing is common.

Can you take AOD 9604 orally?

Yes, the clinical trials actually used oral administration successfully. AOD 9604 is one of the few peptides that shows good oral bioavailability.

However, most users in the biohacking community prefer subcutaneous injection for potentially better absorption and consistency.

Does AOD 9604 affect testosterone or other hormones?

No. AOD 9604 doesn't interact with the HPG axis (hypothalamic-pituitary-gonadal axis) and won't affect testosterone, estrogen, or other sex hormones.

There's no need for PCT (post-cycle therapy) after using AOD 9604.

Can women use AOD 9604?

Yes. Because AOD 9604 doesn't affect sex hormones or have androgenic properties, it's equally applicable to women.

The dosing protocols are typically the same regardless of gender. For women-specific protocols, see our guide on intermittent fasting for women over 50.

Does AOD 9604 work without exercise?

It can enhance fat loss without exercise, but results will be minimal without a caloric deficit.

The clinical trials showing failure in the larger study included intensive diet and exercise—suggesting that when lifestyle factors are optimized, AOD 9604's additional benefit becomes harder to detect.

It works best as part of a comprehensive approach, not as a standalone solution.

Is AOD 9604 the same as HGH Fragment 176-191?

They're very similar but not identical. AOD 9604 is a modified version of HGH Fragment 176-191 with a tyrosine substitution at the N-terminus.

This modification was designed to improve stability and potency.

The terms are sometimes used interchangeably, but technically AOD 9604 is the more advanced formulation.

The Bottom Line: Is AOD 9604 Worth It?

AOD 9604 occupies an interesting position in the peptide landscape.

It has more clinical evidence behind it than most peptides (six trials, 925 patients), an excellent safety profile, and a clear mechanism of action.

The research shows it can enhance fat loss—but the effect is modest, not dramatic.

The honest assessment: expect roughly 4 extra pounds of fat loss over a 12-week cycle compared to diet and exercise alone.

For some people, that's meaningful. For others seeking more dramatic results, GLP-1 agonists or more aggressive interventions may be more appropriate.

AOD 9604 may be a good fit if you:

Want to enhance fat loss without stimulants or appetite suppression
Are looking for a peptide with strong safety data
Don't want to affect IGF-1, insulin, or other hormones
Have realistic expectations about modest (not miraculous) results
Are not a competitive athlete subject to drug testing

AOD 9604 is probably not the right choice if you:

Expect dramatic weight loss results
Are a competitive athlete (it's banned)
Want muscle-building effects (it has none)
Aren't willing to maintain a caloric deficit and exercise

As with any peptide or performance compound, consult with a healthcare professional before use, and remember that no peptide replaces the fundamentals: consistent training, proper nutrition, adequate sleep, and stress management.

Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, cure, or prevent any disease or condition. AOD 9604 is not FDA-approved for therapeutic use. Always consult a qualified healthcare professional before using any peptide or supplement. Individual results may vary.

References

Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9.
Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15.
Hausman GJ, Diel P. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. J Endocrinol Metab. 2014.
Ng FM, Sun J, et al. Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone. Hormone Research. 2000;53(6):274-278.
Wittert GA, et al. AOD9604, an orally active peptide for the treatment of obesity: Results of a phase 2b study. Diabetes. 2005;54.